Evidence analysisOctober 21, 2026Health & Science
Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 7, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Imuldosa, containing the active substance ustekinumab, is a biologic medicine authorised by the European Medicines Agency (EMA) as of December 12, 2024. It is classified as a biosimilar to Stelara, meaning it is highly similar in structure, purity, and biological activity to this already authorised medicine. Imuldosa is approved for the treatment of several inflammatory conditions, including moderate to severe plaque psoriasis in adults and children over 6 years, active psoriatic arthritis in adults, and moderately to severely active Crohn’s disease in adults and children weighing at least 40 kg.
The medicine works by targeting two cytokines, interleukin-12 and interleukin-23, which play significant roles in immune system-mediated inflammation in the diseases mentioned. By inhibiting these molecules, Imuldosa reduces inflammation and mitigates symptoms.
The EMA’s decision to authorise Imuldosa is based on comparative studies showing its equivalence to Stelara regarding safety, effectiveness, and pharmacokinetics. A clinical study involving 523 patients with plaque psoriasis demonstrated similar symptom improvement with Imuldosa and Stelara after 8 weeks.
Common side effects linked to ustekinumab medicines include headache and nasopharyngitis, while serious allergic reactions, including anaphylaxis, have been reported rarely. Use of Imuldosa is contraindicated in patients with active clinically important infections.
What the source claims
- Imuldosa is a biosimilar to Stelara with highly comparable properties, enabling it to be authorised without requiring extensive clinical trials of efficacy across all indications.
- It can be administered under medical supervision, using specific dosing schedules depending on the condition — either by subcutaneous injection or intravenous infusion initially, transitioning to subcutaneous injections.
- The medicine is intended for patients who do not adequately respond to, or cannot use, other systemic treatments for their conditions, such as ciclosporin, methotrexate, PUVA for psoriasis, or disease-modifying anti-rheumatic drugs for psoriatic arthritis.
- Safety assessments show a side effect profile consistent with that of the reference medicine, Stelara, supporting its clinical use.
- The EMA will continue monitoring adverse events post-authorisation to ensure ongoing patient safety.
What may be missing from the usual framing
The EMA briefing provides detailed information about the authorisation and clinical evaluation of Imuldosa, but it does not extensively discuss economic factors such as pricing or accessibility compared to Stelara. Biosimilars are generally introduced to foster competition and potentially reduce treatment costs, but this aspect is not covered in the source.
Additionally, while the summary includes comparison data for plaque psoriasis, it is less detailed about direct clinical trial data for psoriatic arthritis and Crohn’s disease with Imuldosa specifically. Instead, it relies on the established effectiveness of ustekinumab from Stelara studies, assuming similar outcomes based on biosimilarity.
The source does not describe long-term safety data beyond the initial studies or real-world effectiveness after market introduction, which could be relevant for clinicians and patients considering switching to or initiating Imuldosa.
Competing evidence or uncertainty
The source does not present conflicting evidence or highlight notable uncertainty regarding Imuldosa’s efficacy or safety. However, the principle of biosimilarity means that while structural and functional similarity can be rigorously demonstrated, minor variations that do not affect clinical outcomes might still exist. Long-term post-marketing surveillance data are necessary to confirm that no unforeseen adverse effects emerge over time.
Furthermore, patients and clinicians sometimes express concerns about switching from an originator biologic to a biosimilar, related to immunogenicity and treatment response variability. Such issues are not discussed in the EMA source, and independent studies or real-world evidence would help clarify these aspects.
Why it matters
The approval of Imuldosa as a biosimilar offers potentially more treatment options for patients suffering from chronic inflammatory diseases, especially for those who have inadequate response or intolerance to other systemic therapies. The availability of a biosimilar could help increase market competition, which may improve accessibility and reduce costs in healthcare systems.
Given the chronic and sometimes debilitating nature of psoriasis, psoriatic arthritis, and Crohn’s disease, having safe and effective biologic treatments is crucial for disease management and improving quality of life. Imuldosa’s authorisation based on biosimilarity supports the use of established immunomodulatory mechanisms with potential extended market access.
What to verify next
- Review independent clinical trial data specifically comparing Imuldosa with Stelara in psoriatic arthritis and Crohn’s disease patients to better understand efficacy and safety across all approved indications.
- Monitor real-world studies and pharmacovigilance reports following Imuldosa’s introduction to confirm long-term safety and immunogenicity profiles.
- Investigate any post-authorisation economic analyses evaluating cost savings, prescribing patterns, and patient access impact associated with Imuldosa.
- Consult healthcare providers’ experiences or consensus guidelines addressing biosimilar switching and treatment protocols for patients already receiving ustekinumab-originator therapies.
Readers are encouraged to consult the original European Medicines Agency source for comprehensive details and updates related to Imuldosa’s authorisation, product information, and ongoing risk management measures.
Source & verification
Primary source: What's new · October 20, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…